These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10919947)

  • 1. Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment.
    Schwenk A; Beisenherz A; Römer K; Kremer G; Salzberger B; Elia M
    Am J Clin Nutr; 2000 Aug; 72(2):496-501. PubMed ID: 10919947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy.
    Tang AM; Forrester J; Spiegelman D; Knox TA; Tchetgen E; Gorbach SL
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):230-6. PubMed ID: 12394802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment.
    Schwenk A; Beisenherz A; Kremer G; Diehl V; Salzberger B; Fätkenheuer G
    Am J Clin Nutr; 1999 Nov; 70(5):867-73. PubMed ID: 10539747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in body cell mass and decrease in wasting are associated with increasing potency of antiretroviral therapy for HIV infection.
    Ferrando SJ; Rabkin JG; Lin SH; McElhiney M
    AIDS Patient Care STDS; 2005 Apr; 19(4):216-23. PubMed ID: 15857193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
    Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
    Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India.
    Banerjee T; Pensi T; Banerjee D; Grover G
    Ann Trop Paediatr; 2010; 30(1):27-37. PubMed ID: 20196931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection.
    Ott M; Fischer H; Polat H; Helm EB; Frenz M; Caspary WF; Lembcke B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):20-5. PubMed ID: 7712230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
    Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
    MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
    HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.